SCHEMBL6169151

SCHEMBL6169151

CS(=O)(=O)Nc1ccc(C(=O)Nc2ccc3cc[nH]c3c2)c(NC(=O)OC(c2ccncc2)C2CCNCC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP2 Q8WXD0 1/20 0.39
PIP4K2A P48426 2/20 0.38
PIP4K2B P78356 2/20 0.38
ESR1 P03372 6/20 0.35
CFTR P13569 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRA6 Q16445 1/20 0.35
PYGL P06737 1/20 0.33
ATR Q13535 1/20 0.33
BCL9 O00512 1/20 0.33
CTNNB1 P35222 1/20 0.33
IDH1 O75874 2/20 0.33
TYRO3 Q06418 1/20 0.33
CYP19A1 P11511 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169142 0.76 RXFP2 (0.38) RXFP2PIP4K2APIP4K2BESR1IDH1
SCHEMBL7368537 0.76 RXFP2 (0.40) RXFP2PIP4K2APIP4K2BESR1CFTR
SCHEMBL6169978 0.75 RXFP2 (0.51) RXFP2PIP4K2APIP4K2B
SCHEMBL6169056 0.71 SCN3A (0.34)
SCHEMBL6169059 0.70 ESR1 (0.56) ESR1MEN1KMT2A
SCHEMBL6170463 0.70 RXFP2 (0.52) RXFP2PIP4K2APIP4K2B
SCHEMBL7377861 0.69 RXFP2 (0.45) RXFP2ESR1CFTRGABRA1GABRB1
SCHEMBL5226962 0.68 CYP17A1 (0.36) SLC6A4MEN1ALDH1A1KMT2A
SCHEMBL1607103 0.66 PIP4K2A (0.64) PIP4K2APIP4K2BESR1CYP19A1MAOA
SCHEMBL5224710 0.66 SLC6A4 (0.44) SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US claimed
EP-1019045-B1 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2005-06-08 EP disclosed
US-20030078431-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2003-04-24 US disclosed
US-6500851-B2 ANTICOAGULANT IN MAMMLS ELI LILLY AND COMPANY 2002-12-31 US disclosed
US-20020173518-A1 Antithrombotic agents BEIGHT DOUGLAS WADE (US) 2002-11-21 US disclosed
EP-1019045-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2002-07-03 EP disclosed
US-6372759-B1 BLOOD COAGULATION FACTOR XA FOR MAMMALS ELI LILLY AND COMPANY 2002-04-16 US disclosed
EP-1019045-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-19 EP disclosed
WO-1999000128-A9 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 1999-08-05 WO disclosed
WO-1999000128-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173518-A1 Antithrombotic agents SERPINC1, TFPI, F11 RXFP2 1676/4885PIP4K2A 3424/4885PIP4K2B 3057/4885
US-20030078431-A1 Antithrombotic agents SERPINC1, TFPI, F11 RXFP2 1676/4885PIP4K2A 3424/4885PIP4K2B 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.